摘要
Diabetes is a metabolic disease with a high incidence worldwide, and although existing treatment methods can control blood sugar, there are limitations such as injection dependence, single-target failure, and irreversible decline in β-cell function. In recent years, the discovery that the gut microbiota regulates host metabolism through the "gut-islet axis" has provided new ideas for diabetes treatment. Although traditional probiotics have regulatory potential, they lack targeting and controllability. The rapid development of synthetic biology has given rise to the emerging "live drug" platform of engineered probiotics, which can achieve precise, intelligent, and multifunctional metabolic intervention in the intestine through chassis strain screening, gene circuit design, and delivery enhancement strategies. Engineered probiotics improve the pathological process of diabetes from multiple dimensions through four synergistic mechanisms: glucose homeostasis regulation, inflammation and immune regulation, metabolite-mediated regulation, and intestinal flora remodeling. Preclinical studies have verified its efficacy in lowering glucose, anti-inflammatory, and protecting pancreatic islet function in a variety of animal models, and preliminary progress has been made in safety evaluation. Although in vivo stability, personalized design, mass manufacturing, and regulatory frameworks are still the main challenges in clinical translation, intelligent closed-loop systems, multi-disease synergistic treatment, and combination therapies are showing broad prospects. Engineered probiotics are expected to break through traditional treatment bottlenecks and promote the development of diabetes precision medicine